Were any clinical trials involving dr. paul cox registered on ClinicalTrials.gov and what were their results?

1. Who Paul Alan Cox is and why his trials matter

Paul Alan Cox is an ethnobotanist and director of Brain Chemistry Labs whose work linking island diets and neurodegenerative disease led his team to test L‑serine as a therapeutic candidate; outlets and institutional pages describe FDA‑approved human clinical trials and collaborations with institutions such as Houston Methodist Research Institute ^{[1] [4]}. Fortune and organizational profiles frame his work as moving from ecological observations to human trials, which makes the question of registered trials and public results particularly relevant for clinicians and patients following L‑serine research ^{[2] [5]}.

2. What the public reporting says about trials and scale

Brain Chemistry Labs and affiliated announcements state that in August 2022 a 125‑patient Phase II trial of L‑serine for mild cognitive impairment began in partnership with Houston Methodist Research Institute; earlier reports cite Phase I safety trials in ALS and a six‑month clinical trial published in 2017 showing L‑serine safety in humans ^{[1] [2]}. Fortune’s reporting adds that investigators elsewhere were overseeing Phase II trials in ALS and Alzheimer’s using up to 30 g/day dosing, signaling multiple, concurrent investigator‑led studies beyond Cox’s lab ^[2].

3. ClinicalTrials.gov records: what’s in the provided snippets

The supplied search results include a generic ClinicalTrials.gov link and one record landing page (NCT05174169) without visible content in the snippets ^{[3] [6]}. None of the other provided records includes a ClinicalTrials.gov identifier, direct registry screenshot, or posted results text for the L‑serine trials attributed to Cox or Brain Chemistry Labs in the items you supplied ^{[1] [2]}. Therefore, within the available reporting, ClinicalTrials.gov identifiers and posted results are not shown ^{[3] [1]}.

4. What ClinicalTrials.gov normally contains and why that matters here

ClinicalTrials.gov is the NIH‑operated registry and results database where sponsors or responsible parties register trials and may post basic results; federal rules generally require results reporting for many interventional drug trials within one year of primary completion ^{[6] [7]}. Because the outcomes and compliance timelines vary, the absence of a visible registry identifier in the supplied sources does not prove a trial wasn’t registered or that results weren’t posted — but available sources do not show those registry entries or results ^[7].

5. Conflicting signals and gaps in the public record

Media and organization pages assert that trials were FDA‑approved and underway (including the August 2022 Phase II, 125‑patient study), while the provided ClinicalTrials.gov snippets do not supply matching registry entries or posted results for those trials ^{[1] [3]}. Fortune’s reporting references published papers and investigator‑led trials but does not itself supply a ClinicalTrials.gov identifier or full results dataset in the supplied snippets ^[2]. That mismatch is a meaningful reporting gap: either registry links were omitted from these source excerpts, or the public registry postings are elsewhere and not captured in your search results ^{[2] [3]}.

6. How to resolve the uncertainty responsibly

To confirm registration and read posted results, consult ClinicalTrials.gov directly and search for sponsors (Brain Chemistry Labs, Institute for Ethnomedicine), principal investigators named in reporting, or keywords such as “L‑serine” plus “mild cognitive impairment” or “ALS” ^{[1] [2] [3]}. The ClinicalTrials.gov Protocol Registration and Results System (PRS) and the record landing pages (e.g., NCT numbers) are where trial statuses and basic results appear; the supplied NCT page snippet (NCT05174169) exists in the results list but its contents were not shown in your sources and should be opened on ClinicalTrials.gov for specifics ^{[3] [8]}.

7. What we can say now, and the limits of the record

Based on the supplied material: reputable outlets and Brain Chemistry Labs report FDA‑approved human trials of L‑serine involving Paul A. Cox and collaborators, including a 125‑patient Phase II study started in August 2022, and prior Phase I safety work in ALS ^{[1] [2]}; the provided search results do not include ClinicalTrials.gov identifiers or posted results for those studies, so available sources do not mention registry entries or result summaries that can be cited here ^{[3] [1] [2]}. That is the responsible journalistic conclusion given the materials you supplied.

If you want, I will (a) open ClinicalTrials.gov and search by sponsor and trial keywords to locate any NCT numbers and posted results, or (b) extract the cited 2017 ALS trial publication details referenced by Fortune for its reported safety findings. Which would you prefer?